

Elrexio, Lunsumio, Talvey and Tecvayli will have additional requirements for most commercial members

Blue Cross Blue Shield of Michigan and Blue Care Network are updating the medical policies for the following medical benefit drugs:

- ElrexioTM (elranatamab-bcmm)
- LunsumioTM (mosunetuzumab-axgb)
- Talvey[®] (talquetamab-tgvs)
- Tecvayli[®] (teclistamab-cqyv)

The requirements in the updated medical policies will apply for most members for dates of service on or after Jan. 1, 2025.

In keeping with the updated medical policy, the following additional requirements will need to be met for treatment with these drugs to be considered medically necessary:

Drug	Additional requirements
Elrexio	The member must not have received a stem cell transplant within 12 weeks of Elrexio administration.
Lunsumio	The member must not have: <ul style="list-style-type: none"> • Received an autologous stem cell transplant within the past 100 days • Received prior treatment with any CAR-T therapy within 30 days of Lunsumio administration
Talvey	The member must not have: <ul style="list-style-type: none"> • Plasma cell leukemia • Received an allogenic stem cell transplant within the past six months • Received an autologous stem cell transplant within the past 12 weeks • Received any prior T-cell redirection therapy within the past three months
Tecvayli	The member must not have: <ul style="list-style-type: none"> • Received an allogenic stem cell transplant within the past six months • Received an autologous stem cell transplant within the past 12 weeks

You can see the full list of requirements in the updated medical policies, which will be available no later than Jan. 1. To view the policies, go to the [Medical Policy Router Search](#) page, enter the name of the drug in the *Policy/Topic Keyword* field and press *Enter*.

Tip: To access the Medical Policy Router Search page, go to bcbsm.com/providers, click *Resources* and then click *Search Medical Policies*.

Some commercial groups won't be subject to these requirements

To determine which Blue Cross and BCN commercial groups participate in the Oncology Value Management program through OncoHealth[®], see the [medical oncology prior authorization program participation list for commercial self-funded groups](#). This list will be updated prior to Jan. 1, 2025.

Note: Blue Cross and Blue Shield Federal Employee Program[®] members and UAW Retiree Medical Benefits Trust members with Blue Cross non-Medicare plans don't participate in the standard prior authorization program.

Additional information

For additional information about drugs covered under the medical benefit, see the following pages of the ereferrals.bcbsm.com website:

- [Blue Cross Medical Benefit Drugs](#)
- [BCN Medical Benefit Drugs](#)

Prior authorization isn't a guarantee of payment. Health care providers need to verify eligibility and benefits for members.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.